

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i>	Attorney's Docket No. 41421.0101 CIP1	Application Serial No. 10/684,203
	Applicant(s) John P. FORD	
Filing Date: October 10, 2003		Group Art Unit: 1614


U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1						
	2						
	3						
	4						
	5						


FOREIGN PATENT DOCUMENTS								
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation	
							YES	NO
	6							
	7							
	8							

OTHER DOCUMENTS		
<i>(including author, title, date, pertinent pages, etc.)</i>		
Examiner Initials	Ref. No.	Title
[Signature]	9	Chua D. et al., Proc Am Soc Clin Oncol 22. "Efficacy of capecitabine monotherapy in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy," p. 511, 2003.
	10	Childress J. et al., American Journal of Clinical Oncology, Vol. 26, No. 5. "Cutaneous Hand and Foot Toxicity Associated with Cancer Chemotherapy," pp. 435-436, Oct. 2003
	11	Powis, G., International Encyclopedia of Pharmacology and Therapeutics, Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents," pp 42-50, 1994
	12	Elasmar, et al., Jpn J Clin Oncol 2001; 31(4)172-174. "Case Report: Hand-Foot Syndrome Induced by Oral Fluoropyrimidine S-1
	13	Ehrlanger M. et al., Dermatologica 140, Suppl. I. "Cutaneous Absorption and Urinary Excretion of 6-14C-5-Fluorouracil Ointment Applied in an Ointment to Healthy and Diseased Human Skin," pp. 129-136, 1970.
	14	Fischel J-L., et al., Proceedings of the American Association for Cancer Research, Vol. 45. "Experimental arguments for a better understanding of hand-foot syndrome under capecitabine," p. 487, March 2004.
	15	Findlay M. et al., Annals of Oncology 7:47-53. "Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients in protracted venous infusion with or without interferon- α ," pp. 111-117, 1996
	16	Fujii S. et al., Gann, 70. "Effect of Coadministration of Uracil or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents," pp. 209-214, April, 1979
	17	Fukushima S, et al., Cancer Research 52. "Carcinogenicity of Uracil, a Nongenotoxic Chemical, in Rats and Mice and I Rationale," pp. 188-193, April 1, 1992
	18	Gallo R, et al., The Journal of Clinical Investigation, Vol. 48, "The Enzymatic Mechanisms for Deoxythymidine Synthesis in Human Leukocytes," pp. 82-93, 1969
[Signature]	19	Hatfield D., et al., The Journal of Biological Chemistry. "Synthesis of (3-Ribosyluric Acid) 5'-Phosphate and (3-Ribosylxanthine) 5'-Phosphate by a Pyrimidine Ribonucleotide Pyrophosphorylase of Beef Erythrocytes," pp. 60-66, August 1964

EXAMINER: [Signature]	DATE CONSIDERED: 10/10/04
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	

Form PTO-1449		Attorney's Docket No. 41421.0101 CIP1	Application Serial No. 10/684,203
INFORMATION DISCLOSURE STATEMENT		Applicant(s) John P. FORD	
		Filing Date: October 10, 2003	Group Art Unit: 1614
(use several sheets if necessary)			
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)			
20	Paulo Hoff, Investigational New Drugs 18. "The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL™) and S-1: a review of their clinical development and therapeutic potential," pp. 153-163, 2000		
21	Ichikawa W., et al., British Journal of Cancer (2003) 89. "Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer," 2003 Cancer Research UK		
22	Ikenaka K., et al., Gann, 70. "Effect of Uracil on Metabolism of 5-Fluorouracil <i>in Vitro</i> ," pp. 353-359, June, 1979		
23	Johnson M., et al., Clinical Cancer Research, Vol. 5. "Life-Threatening Toxicity in a Dihydropyrimidine Dehydrogenase-Deficient Patient after Treatment with Topical 5-Fluorouracil," pp. 141-146, August 1999		
24	Kawaguchi Y., et al., Gann, 71. "Studies on the Metabolism of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Uracil Co-Administered Orally to Tumor-Bearing Rats," pp. 889-899, December, 1980		
25	Largillier R., et al., General Poster Session. "Prospective Analysis of Dihydropyrimidine Dehydrogenase (Dpd) Activity for Predicting Capecitabine-Related Toxicities in Metastatic Breast Cancer Patients," p. 39, Mon, 9:00 AM - 1:00 PM, 2002		
26	Leo S., et al., Journal of Chemotherapy, Vol. 6, n. 6 "Dermatological Toxicity from Chemotherapy Containing 5-Fluorouracil," pp. 2-5, 1994		
27	Levy S., et al. Clinical Therapeutics/Vol. 23, No. 6, "A Pharmacokinetic Evaluation of 0.5% and 5% Fluorouracil Topical Cream in Patients with Actinic Keratosis," pp. 908-920, 2001		
28	Luccioni, et al., Int. J. Cancer: 58, "Pyrimidine Nucleotide Metabolism in Human Colon Carcinomas: Comparison of Normal Tissues Primary Tumors and Xenografts," pp. 32-37, 1994		
29	Mackean M., et al., Journal of Clinical Oncology, Vol. 16, No. 9, "Phase I and Pharmacologic Study of Intermittent Twice-Daily Oral Therapy with Capecitabine in Patients with Advanced and/or Metastatic Cancer," pp. 2977-2985, September, 1998		
30	Maehara Y., et al., Oncology, Vol. 11, No. 9, "Scientific Basis for the Combination of Tegafur with Uracil," pp. 14-21, Supplement No. 10, 2001		
31	Malet-Martino M., et al., The Oncologist 2002, "Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review," pp. 288-323		
32	Niedzwicki J., et al., Biochemical Pharmacology, Vol. 32, No. 3, "Structure-Activity Relationship of Ligands of the Pyrimidine Nucleoside Phosphorylases," pp. 399-415, 1983		
33	Niedzwicki J., et al., Biochemical Pharmacology, Vol. 33, No. 15, "Structure-Activity Relationship of Pyrimidine Base Analogs as Ligands of Orotate Phosphoribosyltransferase," pp. 2383-2395, 1984		
34	Naguib, et al., Cancer Research 45, "Enzymes of Uracil Catabolism in Normal and Neoplastic Human Tissues," pp. 5405-5412, November 1985		
35	Spicer E., et al., "Toxicity Study of Uracil in Dogs," pp. 199-204, 2003		
36	Senff H., et al., British Journal of Dermatology 118, "Topical 5-Fluorouracil Solution in the Treatment of Warts—Clinical Experience and Percutaneous Absorption," pp. 409-414, 1988		
37	Sawada N., et al., Clinical Cancer Research, Vol. 4, "Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine Efficacy by Taxol/Taxotere in Human Cancer Xenografts," pp. 1013-1019, April 1998		
38	Sludden J., et al., Pharmacology, "Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse," pp. 276-280, 1998		
39	Wang J., et al., Anticancer Research 24, "Oral 5-FU is a More Effective Antimetastatic Agent than UFT," pp. 1353-1360 (2004)		
EXAMINER: <i>[Signature]</i>		DATE CONSIDERED: 11/1/04	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).			

Form PTO-1449		Attorney's Docket No. 41421.0101 CIP1	Application Serial No. 10/684,203
INFORMATION DISCLOSURE STATEMENT		Applicant(s) John P. FORD	
(use several sheets if necessary)		Filing Date: October 10, 2003	Group Art Unit: 1614
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)			
	40	Ichikawa W., et al., Gastrointestinal Cancer, "Polymorphisms of orotate phosphoribosyl transferase (OPRT) gene and thymidylate synthase tandem repeat (TSTR) predict adverse events (AE) in colorectal cancer (CRC) patients treated with 5-fluorouracil (FU) plus leucovorin (LV)," p. 1063, 2003	
	41	Schilsky R.L., et al., Food and Drug Administration Center for Drug Evaluation and Research, "Sixty-Third Meeting of the Oncologic Drug Advisory Committee", Sept. 16, 1999	
	42	Unknown, Oncology News International, "Lower Dose Capecitabine Is Active and Has Favorable Safety Profile in Elderly Patients With Advanced Breast Cancer," p. 40, August 2003	
	43	Unknown, Roche Pharmaceuticals, "Xeloda (capecitabine) Tablets," April 2003	
	44	Samid, D., Roche Laboratories Inc., "Important Information About Xeloda (capecitabine) Tablets," August 2003	
	45	Hartmann, H.R., et al., Med. Oncol. & Tumor Pharmacother." Vol. 3 No. 2, "Modulation of the Effects of Fluoropyrimidines on Toxicity and Tumor Inhibition in Rodents by Uridine and Thymidine," pp. 111-118, April 25, 1986	
	46		
	47		
48			

EXAMINER: 	DATE CONSIDERED: 6/1/04
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	